Introduction
HIV infection is characterized by chronic immune activation, uncontrolled viral replication and a loss of CD4 þ T cells, resulting in progression to AIDS. A population of rare individuals (approximately 1% of the HIV-infected population) has been shown to maintain clinically undetectable plasma viral loads (<75 copies/ml) in the absence of therapy ('elite controllers') [1, 2] . Elite controllers have decreased T-cell activation [3, 4] and stronger HIV-specific CD4 þ T-cell interferon-g (IFNg) and interleukin-2 responses targeted toward the Gag protein than individuals who do not control HIV replication [5] .
It is well documented that there is an increase in the level of CD4 þ and CD8 þ T cells expressing 'activation' markers such as CD38, human leukocyte antigen-DR (HLA-DR) and/or Ki67 expression in HIV infection [3, [6] [7] [8] [9] . For reasons that have not yet been fully defined, a higher frequency of these cells is associated with more rapid disease progression, independent of viral load and CD4 þ T-cell counts [3, [10] [11] [12] . Recent studies by our group found that despite having undetectable viral loads, elite controllers had higher levels of immune activation than HIV seronegatives and HAART-suppressed individuals [2, 3] . The mechanism accounting for this higher than expected level of immune activation is not known, but may be due to higher levels of HIV production, higher levels of microbial translocation, and/or lower levels of immunoregulatory cells.
As immune activation appears to play an adverse role in HIV infection, cells with the ability to decrease inflammation may be beneficial. Regulatory T (Treg) cells are a unique population of CD4 þ T cells that have the ability to suppress the activation and proliferation of T cells [13] [14] [15] [16] . This population of CD4 þ T cells has traditionally been identified by the expression of CD25 and the transcription factor FoxP3, and more recently in combination with other markers including CD127 and CD152 [13, [17] [18] [19] [20] [21] [22] [23] . Studies of the role of Treg cells in HIV infection show conflicting results. Some studies have shown an increase in the number of Treg cells in HIV infection [24] [25] [26] , whereas others have shown a decrease [27] [28] [29] [30] [31] [32] . Higher levels of Treg function could prevent some of the harmful effects of immune activation on disease progression, whereas lower levels could allow a strong and durable antigen-specific T-cell response.
Finally, cytokine and chemokine profiles may differ between elite controllers and noncontrollers. However, there is considerable variability in the levels of cytokines produced between infected individuals [33] [34] [35] [36] [37] [38] . Studies of the earliest phase of HIV infection in plasma donors acquiring HIV revealed a striking pro-inflammatory cytokine cascade beginning within days of the first appearance of viremia [39, 40] . Although there have been numerous studies of cytokine profiles in HIV infection, broad analysis of the cytokine responses in elite controllers has not been reported.
Despite strong and growing interest in the elite controllers as a model for understanding the optimal HIV-specific host response, no study to our knowledge has attempted to fully characterize the nature of the T-cell response in these individuals. In our current study we assessed the activation and proliferation status of antigenspecific CD4 þ and CD8 þ T cells, the cytokine and chemokine response to HIVand cytomegalovirus (CMV) stimulation, and the number of Treg cells in four groups of individuals. Our sample cohort included HIV seronegative individuals and three classes of HIV-infected individuals: elite controllers, HAART-suppressed individuals and noncontrollers. One sample from each individual was assessed for all parameters at the same time point, with the goal of identifying immunological factors that drive the maintenance of robust T-cell responses and control of viral replication in elite controllers in the absence of therapy.
Methods

Study individuals
Blood samples were obtained from HIV-infected individuals enrolled in the University of California, San Francisco (UCSF) SCOPE cohort and from 20 healthy HIV seronegative individuals. All individuals underwent informed consent under protocols approved by the UCSF Committee on Human Research. HIV-infected individuals were divided into three groups. (1) Elite controllers, at least two viral loads less than 75 copies/ml spanning 6 months or more (median of 10 undetectable viral loads/ individual). A viral load more than 1000 copies were recorded in three individuals over 4.5 years prior to study sample acquisition. Three controllers had antiretroviral therapy (ART) exposure 7, 10 and 14 years prior to study.
(2) HAART-suppressed, antiretroviral treated with at least two viral loads less than 75 copies/ml spanning 12 months or more. (3) Noncontrollers, untreated with an index viral load more than 10 000 copies/ml ( Table 1) . As advanced immunodeficiency can cause T-cell dysfunction, we excluded from our analysis any individual with a CD4 þ T-cell count less than 300 cells/ml.
Stimulation of peripheral blood mononuclear cells
Cryopreserved peripheral blood mononuclear cells (PBMC) were rapidly thawed into RPMI supplemented 1096 AIDS 2010, Vol 24 No 8 Gating on CD4 þ CD25 þ CD127 À CD152 þ T cells has been shown to define Treg cells [18, 19, 23, 41] . Our results were consistent with these prior studies showing that this population was also FoxP3 þ (data not shown). Activation panel intracellular staining was accomplished using Cytofix and Cytoperm reagents (BD Biosciences) and Treg intracellular staining was performed using a Foxp3 staining buffer set (eBioscience, San Diego, California, USA) according to the respective manufacturer's instructions. Compensation controls included CompBeads or cells stained with equivalent quantities of test antibody. Fluorescence minus one (FMO) and isotype-stained controls were used to set gating. Gates for IFNg were set using unstimulated negative control samples.
The Treg panel was acquired on an LSRII Flow Cytometer (BD Biosciences) and the activation panel on a FACS Aria (BD Biosciences). Instrument set-up was standardized to reduce batch-to-batch variation. Preoptimized target channel voltages were set using midrange FL1 rainbow fluorescent particles (BD Biosciences). Single stained compensation tubes were checked to ensure each stain was the brightest in its own channel.
A median of 150 000 viable CD3 þ events was collected for each panel. Data were analyzed using FlowJo 8.7.3 software (TreeStar, Ashland, Oregon, USA).
Multiplex cytokine and chemokine analysis
Supernatants were assayed using the high-sensitivity LincoPlex kit (Millipore, Billerica, Massachusetts, USA) for interleukin-1b, interleukin-2, interleukin-4, interleukin-5, interleukin-6, interleukin-7, interleukin-8, interleukin-10, interleukin-12 p70, interleukin-13, IFNg, granulocyte-macrophage colony stimulating factor (GM-CSF) and tumor necrosis factor-a (TNFa), and the standard- 
Results
Cohort characteristics
Individuals from four groups were studied, HIV negatives, HIV elite controllers, HAART-suppressed and HIV noncontrollers, including 18 HIV elite controllers and 20 of each of the other groups. Most individuals were men, and the median age for the respective groups was 43, 48, 53 and 44 years ( Table 1 ). The median CD4 þ T-cell counts for the controllers, HAART-suppressed and noncontrollers were 764, 725 and 588 cells/ml (CD4 þ T-cell counts were not available for the HIV seronegatives).
Elite controllers have the lowest levels of HIVspecific T-cell activation For unclear reasons, at least a subset of elite controllers are able to maintain vigorous HIV-specific T-cell responses for extended periods, with some patients now known to be able to maintain control for up to 30 years. It is known that elite controllers have high frequencies of HIVspecific CD4 þ and CD8 þ T cells and intermediate levels of general T-cell activation when compared with HIV uninfected or HAART-suppressed individuals (low activation) and noncontrollers (high activation) [3, 5] , and we confirmed those findings in the current study (data not shown). However, we hypothesized that HIV-specific cells might be relatively less activated in elite controllers compared with noncontroller individuals. We defined activated HIV-specific cells as those co-expressing CD38 and HLA-DR (gated on IFNg þ cells following HIV p55 stimulation, Fig. 1a ). We found significantly lower levels of activated CD8 þ but not CD4 þ HIV-specific T cells among elite controllers and HAART-suppressed individuals compared with noncontrollers ( Fig. 1b, c) . Elite controllers also showed the lowest levels of recently divided HIVspecific CD4 þ T cells (expressing Ki67), and their numbers were significantly lower than noncontrollers and HAARTsuppressed individuals (Fig. 1d ). There was no significant difference in the turnover of HIV-specific CD8 þ T cells among the HIV þ groups (Fig. 1e ).
The lower levels of HIV-specific CD8 þ T-cell activation in elite controllers could have been due to decreased antigen exposure in individuals with lower viral load, as recently suggested [42] [43] [44] . To test this we measured activation of CMV-specific T cells and found no significant differences compared with noncontrollers ( Fig. 2a,  b) . These results imply that the increased activation seen in HIV-specific CD8 þ T cells from noncontrollers is due to greater antigenic stimulation compared with elite controllers. It has recently been suggested that CD4 þ T-cell proliferation [measured by bromodeoxyuridine (BrdU) staining] is determined by both CD4 þ T-cell depletion and HIV viral burden [43] . One would expect that response to CD4 þ T-cell depletion would occur equally in HIV-specific and CMV-specific CD4 þ T-cells, whereas HIV viral burden would induce more proliferation in HIV-specific CD4 þ T-cells in an antigen-specific fashion or equally affect HIV-specific and CMV-specific T cells through direct mechanisms such as infection of activated cells or induction of bystander apoptosis. Consistent with viral burden rather than CD4 þ T-cell depletion driving proliferation, frequencies of recently divided CMV-specific T cells were lower compared with HIV-specific T cells among noncontrollers (P < 0.001 and P < 0.05 for CD4 þ and CD8 þ T cells, respectively). Additionally, the CMV-specific T cells showed no increase in recently divided cells in noncontrollers compared with elite controllers (Fig. 2c, d) , illustrating no global increase in proliferation of antigen-specific cells in noncontrollers compared with elite controllers.
Elite controllers mount broad and vigorous HIVspecific cytokine responses
Elite control of HIV infection has been shown to correlate with the presence of cells able to secrete IFNg, interleukin-2, TNFa and MIP-1b. We aimed to extend these observations by focusing on other factors that might be preferentially expressed in T cells from elite controllers. Stimulation with p55 induced pro-inflammatory cytokines and chemokines, including interleukin-2, IFNg, TNFa, inducible protein-10, GM-CSF, MCP-3 and MIP-1b. PBMC from elite controllers produced significantly more IFNg, GM-CSF, inducible protein-10, MCP-3, TNFa and interleukin-2 than the HIV seronegative individuals after p55 stimulation (Fig. 3a) . In contrast, the HAART-suppressed group only produced significantly more IFNg and inducible protein-10 upon p55 stimulation compared with the HIV seronegative individuals. The HAART-suppressed group also produced more interleukin-2 and interleukin-13 than the noncontrollers (Fig. 3a) . The noncontrollers produced the lowest levels of HIV-induced cytokines, only secreting IFNg and inducible protein-10 ( Fig. 3a) . The noncontrollers had the lowest mean-fold increase in IFNg compared with elite controllers and HAARTsuppressed individuals (mean-fold change of 31.69 versus 424.23 for elite controllers and 246.50 for HAARTsuppressed). The noncontrollers also secreted less TNFa, GM-CSF and MCP-3 than the elite controllers ( Fig. 3a) .
Collectively, these data demonstrate the elite controllers can produce a wide breadth of cytokines and chemokines after HIV stimulation, including antiviral factors such as MIP-1b.
Stimulation of PBMC with the CMV pp65 peptide pool induced cytokines and chemokines to the same degree in all groups, with the exception of noncontrollers who produced significantly less MDC than HIV seronegative individuals and less GM-CSF than HAART-suppressed individuals (Fig. 3b) . Therefore, the alterations in the cytokine and chemokine environment were HIV-specific and not a result of general immune activation resulting from a chronic viral infection.
Elite controllers have no elevation in the number of regulatory T cells
The decreased levels of activation and proliferation seen in HIV-specific T cells from elite controllers may have been due to higher magnitude Treg cell levels in the elite controllers. We defined Treg cells as CD4 þ CD25 þ CD127 À CD152 þ (Fig. 4a) . The frequency and absolute number of these cells in the elite controllers were comparable with that in HIV seronegatives and noncontrollers, whereas the HAART-suppressed patients showed an elevated percentage of Treg cells compared with HIV seronegatives and elevated absolute Treg cell numbers compared with noncontrollers (Fig. 4b, c) . We found no IFNg, interferon-g.
( Fig. 4d) . However, when all samples (both HIV þ and HIV À ) were analyzed, a positive correlation between the frequency of Treg cells and age was found (data not shown, P < 0.05). The HAART-suppressed group, which had the highest frequency and absolute number of Treg cells, also had the oldest median age of 53 years (range 35-80 years), significantly older than the median age of the HIV seronegative individuals and the HIV þ noncontrollers ( Table 1 , P < 0.05 for both comparisons).
Multivariable linear regression analysis showed that after adjusting for age and CD4 þ cell count, HAART was significantly associated with a 0.60% increase in the frequency of Treg cells on average (P ¼ 0.03). Age (P ¼ 0.63) and CD4 cell count (P ¼ 0.60) were not significantly associated with an increase in the frequency of Treg cells.
Discussion
We found that elite controllers maintained lower levels of activated HIV-specific CD8 þ and recently divided HIV-specific CD4 þ T cells compared with noncontrollers, and this was not explained by increased proportions of Treg cells in elite controllers. Decreased antigen-specific T-cell activation was limited to the HIVspecific subsets of cells and was not found in the respective CMV-specific populations. Additionally, the elite controllers possessed the strongest and broadest HIV-specific immune responses, with seven cytokines and chemokines induced by HIV stimulation (interleukin-2, IFNg, TNFa, GM-CSF, inducible protein-10, MCP-3 and MIP-1b). In summary, elite controllers maintained the strongest HIV-specific immune responses, with markers these individuals only secreting significant amounts of interleukin-2, IFNg and inducible protein-10. Interestingly, HAART suppression was associated with the production of interleukin-13, a cytokine involved in B cell growth and differentiation that can inhibit macrophage inflammatory cytokine production. The reduction of inflammatory cytokines could also be responsible for the reduction in T-cell activation and proliferation seen during HAART treatment. Our multiplex cytokine testing data support previous reports of viral control being associated with polyfunctional T-cell responses [42, 45, 46] , and the cytokines identified above further clarify which specific responses are associated with control of viral replication during chronic HIV infection.
The increase in the number of Treg cells following HAART that we observed is consistent with some previous studies. Weiss [48] . Two other studies showed no effect of HAARTon Treg cell numbers despite suppression of viral replication and immunological recovery [49, 50] . The precise mechanism of Treg cell expansion during HAART remains unknown and requires further investigation. An increase in the peripheral Treg cell pool by proliferation, increased survival of Treg cells or an increase in the thymic generation of Treg cells all could be responsible [41, [51] [52] [53] . As we saw no correlation between the number of Treg cells and HIVspecific or CMV-specific T-cell responses (data not shown), it would appear that Treg cells do not strongly interfere with HIV-specific immune responses, raising the possibility of inducing these cells to ameliorate the effects of immune activation in the setting of high viral loads during chronic HIV infection.
Although our data mostly agree with those of Chase et al. [54] , we did see a difference in which HIV-infected group had the highest number of Treg cells. Elite controllers in the Chase et al. study had the highest number of Treg cells, whereas we saw the highest number of Treg cells in our HAART-suppressed group. One possible explanation for this is confounding by age, as older individuals have higher Treg cell numbers [55] [56] [57] . In both our study and the Chase study the groups with the highest number of Treg cells were also the oldest. In the Chase study elite controllers were the oldest (median age ¼ 54 years), whereas their HAART-suppressed group was the youngest (median age ¼ 46 years). In contrast, our HAARTsuppressed group was the oldest (median age ¼ 53 years) and the elite controllers were younger (median age ¼ 48 years). Multivariate analysis of our data, which controlled for confounding by age, showed that the increase in Treg cells was due to the therapy and not age. Whether this would be the case in the Chase et al. study [54] was not addressed.
In conclusion, lower levels of HIV-specific T-cell activation and in-vivo proliferation combined with stronger, broader HIV-specific cytokine responses likely play a role in the control of HIV infection by elite controllers. However, elite controllers do not completely clear the virus [2] and may eventually lose their elite status and progress toward the development of AIDS [1, 3] . A therapeutic vaccine or immune modulation that could reduce immune activation, potentially by the induction of Treg cells, and generate a more appropriate balance of immune responses (such as those seen in elite controllers) may allow noncontrollers to decrease HIV replication and delay the progression to AIDS.
